Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

47.45 +0.39 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,813,170
Open 47.54
Bid (Size) 45.92 (10)
Ask (Size) 47.80 (5)
Prev. Close 47.06
Today's Range 45.70 - 47.85
52wk Range 45.52 - 77.32
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety

Performance

YTD
-19.71%
-19.71%
1 Month
-16.25%
-16.25%
3 Month
-21.94%
-21.94%
6 Month
-28.76%
-28.76%
1 Year
-30.28%
-30.28%

More News

Read More
Analyst Ratings For Legend Biotech
Via Benzinga
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
From Legend Biotech Corporation
Via Business Wire
Unveiling 9 Analyst Insights On Legend Biotech
Via Benzinga
Earnings Preview: Legend Biotech
Via Benzinga
What 4 Analyst Ratings Have To Say About Legend Biotech
Via Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
Via Benzinga
Exposures Product Safety
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Via Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
From Legend Biotech Corporation
Via Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Via Benzinga
Exposures Product Safety
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Via Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Earnings Scheduled For March 11, 2024
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Via Talk Markets
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
From Legend Biotech Corporation
Via Business Wire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
Via Benzinga
Exposures Product Safety
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Via Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.